Internship

Co-op – Chemical Engineering: July

Posted on 4/19/2025

Insulet Corporation

Insulet Corporation

1,001-5,000 employees

Develops tubeless insulin delivery systems

Compensation Overview

$24 - $28.50/hr

Massachusetts, USA

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • Currently pursuing Bachelor of Science in Chemistry/Chemical Engineering /Biology
  • Ability to work with chemistry-based lab equipment and tools
Responsibilities
  • Follow safety guidelines
  • Maintain electronic and/or paper notebooks
  • Author/Establish Tool Files for instruments/procedures in chemistry lab
  • Use GCMS and conduct outgassing studies on batteries, adhesive pads and other components for Omni Pods with headspace autosampler, and analyze liquid extraction samples with liquid autosampler
  • Use FTIR for investigation of foreign matter related to R&D, post market or manufacture
  • Conduct Conductivity testing when needed
  • Maintain/update system level data sheet for Omni Pod
  • Coordinate sample submission to Contract labs
  • Author Test Protocol/Test Report for biocompatibility as needed
  • Help out/lighten other groups’ workload as needed
Desired Qualifications
  • Highly ethical, responsible and data-driven decision making methodology
  • Effective verbal and written communication skills
  • Ability to follow direction
  • Proficient in Microsoft Office Tools (Word, Excel, PowerPoint a plus)

Insulet Corporation focuses on creating medical devices that make life easier for individuals with diabetes and other health conditions. Their main product, the Omnipod Insulin Management System, offers a different approach to insulin delivery compared to traditional methods. The Omnipod is a tubeless, disposable device that can deliver insulin continuously for up to three days without the need for needles. A key feature of the Omnipod 5 Automated Insulin Delivery System is its ability to work with a continuous glucose monitor, allowing users to manage their blood sugar levels without daily injections or finger pricks. This system can be controlled via a smartphone or a dedicated controller. Insulet stands out from its competitors by providing a simple, wearable solution that eliminates the hassle of traditional insulin delivery methods. The company's goal is to improve the quality of life for people with diabetes by offering convenient and effective insulin management solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Insulet raised $444.4M to optimize capital structure and support growth.
  • Omnipod 5's expansion into five European countries boosts international presence.
  • Winning $452M in a trade secrets trial strengthens Insulet's financial position.

What critics are saying

  • Emerging diabetes care companies may challenge Insulet's market share.
  • Technological advancements require continuous R&D investment to stay competitive.
  • Supply chain vulnerabilities in semiconductor components could disrupt production.

What makes Insulet Corporation unique

  • Insulet leads in tubeless insulin pump technology with its Omnipod brand.
  • The Omnipod 5 integrates with Dexcom G7 CGM, enhancing diabetes management.
  • Insulet's multinational RADIANT trial showcases innovation in transitioning from daily injections.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Financial Modeling Prep
Mar 28th, 2025
Insulet Corporation's Financial Efficiency in the Medical Device Industry

Insulet competes with companies like DexCom, Tandem Diabetes Care, and Masimo Corporation in the diabetes care market.

Stock Titan
Mar 18th, 2025
Insulet Secures $450M Through Senior Notes Offering: Key Details on Strategic Debt Refinancing

Insulet raises $444.4M through senior notes to refinance existing convertible debt. Strategic move positions medical device maker for future growth while optimizing capital structure.

Stock Titan
Mar 18th, 2025
From Injections to Innovation - Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod(R) 5 in Adults and Children with Type 1 Diabetes

Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025.

Path8 Video
Mar 11th, 2025
Insulet product launch video

This video helped Insulet launch its new iPhone app.

Financial Modeling Prep
Mar 6th, 2025
Ubiquiti Inc. (NYSE:UI) Outshines Peers in Capital Efficiency

Ubiquiti competes with companies like Fair Isaac Corporation, Paylocity Holding Corporation, Monolithic Power Systems, EPAM Systems, and Insulet Corporation.

INACTIVE